Back to Results

LianBio ADR (LIANY)

LianBio ADR is a depositary receipt listed on OTC Markets that represents the common stock of LianBio. The underlying issuer is a biotechnology company focused on developing medicines for cardiovascular, oncology, ophthalmology, and inflammatory disease indications in China and other Asian countries. Its pipeline includes mavacamten for obstructive hypertrophic cardiomyopathy, which is in the Phase 3 EXPLORER-CN trial; TP-03 for Demodex blepharitis and meibomian gland disease, which is in the Phase 3 LIBRA trial; NBTXR3 for head and neck squamous cell carcinoma and other solid tumors; Infigratinib for FGFR2 gene amplification; and BBP-398 for solid tumors. LianBio was incorporated in 2019 and is headquartered in Princeton, New Jersey.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Analyst Price Target Analyst Target Upside/Downside Overall Financial Health Dividend Yield Next Earnings Date Market Cap
OTC-LIAN.Y
Not available
Not available
Not available
Excellent
0.0%
November 17, 2026
6.436 M
Valuation • Fair Value

LianBio ADR (OTC-LIAN.Y) Fair Value by Valuation Model

No usable valuation estimate is currently available for LianBio ADR (OTC-LIAN.Y); fair value and analyst target coverage statuses are shown explicitly below.

Primary Valuation Read

Fair Value

Not available

Data is currently unavailable.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

No usable valuation estimate is currently available for LianBio ADR (OTC-LIAN.Y). Fair value and the analyst target remain visible as coverage-status fields and should not be read as valuation signals while unavailable.

Profitability • Growth

Profitability & Growth for LianBio ADR (OTC-LIAN.Y)

Review the profitability and growth indicators currently supported by the latest data.

EBITDA

0 K

Current operating profitability reference.

How to read profitability and growth

This section helps investors review LianBio ADR (OTC-LIAN.Y) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for LianBio ADR (OTC-LIAN.Y)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Excellent

Positive financial-health read.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for LianBio ADR (OTC-LIAN.Y). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for LianBio ADR (OTC-LIAN.Y)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 17, 2026

Days to Earnings

60

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for LianBio ADR (OTC-LIAN.Y), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

LianBio ADR (OTC-LIAN.Y) Stock Forecast & Technical Outlook

Review LianBio ADR (OTC-LIAN.Y) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Neutral

The 15-minute technical read for LianBio ADR (OTC-LIAN.Y) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Neutral

The 1-hour technical read for LianBio ADR (OTC-LIAN.Y) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Buy

The daily technical read for LianBio ADR (OTC-LIAN.Y) is currently Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for LianBio ADR (OTC-LIAN.Y) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for LianBio ADR (OTC-LIAN.Y) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for LianBio ADR (OTC-LIAN.Y)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Hold

Based on the available recommendation mix, LianBio ADR (OTC-LIAN.Y) has a Hold consensus, with 0 buy, 1 hold and 0 sell recommendations in the current data set.

Buy 0
Hold 1
Sell 0
FAQ • Fast Investor Answers

LianBio ADR (OTC-LIAN.Y) Stock FAQ

Data-supported answers about LianBio ADR (OTC-LIAN.Y), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
Not available
No reliable estimate from the currently supported inputs
Financial Health
Excellent
Current financial-health read

A reliable fair value estimate is not currently available for LianBio ADR (OTC-LIAN.Y). This generally means the latest dataset does not contain enough valid inputs for the valuation models supported by PriceToWorth. The site does not substitute zero or publish an unsupported estimate; availability may change when updated financial data or applicable model inputs become available.

The current financial health read for LianBio ADR (OTC-LIAN.Y) is Excellent. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for LianBio ADR (OTC-LIAN.Y) is November 17, 2026.

The latest available data indicates no current dividend yield for LianBio ADR (OTC-LIAN.Y).

The current market capitalization listed for LianBio ADR is 6.436 M.

The ticker symbol for LianBio ADR is OTC-LIAN.Y, and the stock is listed on OTC Markets.

LianBio ADR (OTC-LIAN.Y) is listed on OTC Markets.

Similar Biotechnology Stocks View more on OTC Markets

Comparable companies from the same industry, limited to one security per issuer.

ABBV NYSE AbbVie Inc Fair Value Fair Market Cap 466.4 B
AMGN NASDAQ Amgen Inc Fair Value Fair Market Cap 208.5 B
GILD NASDAQ Gilead Sciences Inc Fair Value Fair Market Cap 186 B
VRTX NASDAQ Vertex Pharmaceuticals Inc Fair Value Fair Market Cap 128.8 B
REGN NASDAQ Regeneron Pharmaceuticals Inc Fair Value Undervalued Market Cap 78.353 B
ARGX NASDAQ argenx NV ADR Fair Value Fair Market Cap 62.595 B
MRNA NASDAQ Moderna Inc Fair Value Overvalued Market Cap 61.522 B
NTRA NASDAQ Natera Inc Fair Value Overvalued Market Cap 53.245 B
RVMD NASDAQ Revolution Medicines Inc Fair Value Fair Market Cap 40.928 B
ONC NASDAQ BeOne Medicines AG DRC Fair Value Fair Market Cap 39.9 B
ALNY NASDAQ Alnylam Pharmaceuticals Inc Fair Value Fair Market Cap 32.055 B
BIIB NASDAQ Biogen Inc Fair Value Fair Market Cap 31.841 B
ROIV NASDAQ Roivant Sciences Ltd Fair Value Overvalued Market Cap 28.748 B
INSM NASDAQ Insmed Inc Fair Value Fair Market Cap 26.206 B
INCY NASDAQ Incyte Corporation Fair Value Fair Market Cap 25.4 B
BNTX NASDAQ BioNTech SE Fair Value Fair Market Cap 24.131 B
UTHR NASDAQ United Therapeutics Corporation Fair Value Fair Market Cap 21.214 B
GMAB NASDAQ Genmab AS Fair Value Overvalued Market Cap 20.751 B
ASND NASDAQ Ascendis Pharma AS Fair Value Fair Market Cap 15.546 B
NBIX NASDAQ Neurocrine Biosciences Inc Fair Value Undervalued Market Cap 14.864 B